Ignite Creation Date:
2024-05-05 @ 5:23 PM
Last Modification Date:
2024-10-26 @ 9:31 AM
Study NCT ID:
NCT00448734
Status:
UNKNOWN
Last Update Posted:
2009-01-21
First Post:
2007-03-15
Brief Title:
A Study of Picoplatin and Docetaxel in Subjects With Prostate Cancer
Sponsor:
Poniard Pharmaceuticals
Organization:
Poniard Pharmaceuticals
Study Overview
Official Title:
A Phase 12 Study of Picoplatin and Docetaxel With Prednisone in Subjects With Chemotherapy-Naive Metastatic Hormone-Refractory Prostate Cancer
Status:
UNKNOWN
Status Verified Date:
2009-01
Last Known Status:
ACTIVE_NOT_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will review the safety of picoplatin a new type of platinum drug with docetaxel a drug commonly used in the treatment of prostate cancer Patients who are eligible for this study will have had a diagnosis of hormone-refractory prostate cancer that has metastasized to other areas of the body and have not been previously treated with chemotherapy drugs Picoplatin will be administered in combination with docetaxel and prednisone to identify the maximum tolerated dose MTD Patients will receive IV treatments of picoplatin with docetaxel every 3 weeks with prednisone 5 mg orally twice daily
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None